PI3K inhibition enhances doxorubicin-induced apoptosis in sarcoma cells

We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis. PI103 decreased the expression of MDR1 and MRP1, w...

Full description

Saved in:
Bibliographic Details
Published in:PloS one Vol. 7; no. 12; p. e52898
Main Authors: Marklein, Diana, Graab, Ulrike, Naumann, Ivonne, Yan, Tiandong, Ridzewski, Rosalie, Nitzki, Frauke, Rosenberger, Albert, Dittmann, Kai, Wienands, Jürgen, Wojnowski, Leszek, Fulda, Simone, Hahn, Heidi
Format: Journal Article
Language:English
Published: United States Public Library of Science 31-12-2012
Public Library of Science (PLoS)
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We searched for a drug capable of sensitization of sarcoma cells to doxorubicin (DOX). We report that the dual PI3K/mTOR inhibitor PI103 enhances the efficacy of DOX in several sarcoma cell lines and interacts with DOX in the induction of apoptosis. PI103 decreased the expression of MDR1 and MRP1, which resulted in DOX accumulation. However, the enhancement of DOX-induced apoptosis was unrelated to DOX accumulation. Neither did it involve inhibition of mTOR. Instead, the combination treatment of DOX plus PI103 activated Bax, the mitochondrial apoptosis pathway, and caspase 3. Caspase 3 activation was also observed in xenografts of sarcoma cells in nude mice upon combination of DOX with the specific PI3K inhibitor GDC-0941. Although the increase in apoptosis did not further impact on tumor growth when compared to the efficient growth inhibition by GDC-0941 alone, these findings suggest that inhibition of PI3K may improve DOX-induced proapoptotic effects in sarcoma. Taken together with similar recent studies of neuroblastoma- and glioblastoma-derived cells, PI3K inhibition seems to be a more general option to sensitize tumor cells to anthracyclines.
Bibliography:Competing Interests: The authors have declared that no competing interests exist.
Conceived and designed the experiments: DM UG IN TY FN KD LW SF HH. Performed the experiments: DM UG IN TY RR FN. Analyzed the data: DM UG IN TY RR FN KD AR. Contributed reagents/materials/analysis tools: JW LW SF HH. Wrote the paper: DM LW SF HH.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0052898